CAMBRIDGE, Mass., Nov. 26,
2024 /PRNewswire/ -- Leap Therapeutics, Inc.
(Nasdaq:LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced that
Douglas E. Onsi, President and Chief
Executive Officer, will participate in a fireside chat at the Piper
Sandler 36th Annual Healthcare Conference in
New York, NY.
Leap Presentation Details:
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 4:00 p.m. Eastern Time
A live webcast of the fireside chat may be accessed on the
Investors page of the company's website at
https://investors.leaptx.com/, where a replay of the events will
also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq:
LPTX) is focused on developing targeted and immuno-oncology
therapeutics. Leap's most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in
patients with esophagogastric, colorectal, and gynecological
cancers. Leap's pipeline also includes FL-501, a humanized
monoclonal antibody targeting the growth and differentiation factor
15 (GDF-15) protein, in preclinical development. For more
information about Leap Therapeutics, visit http://www.leaptx.com or
view our public filings with the SEC that are available via EDGAR
at http://www.sec.gov or via https://investors.leaptx.com/.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-302313181.html
SOURCE Leap Therapeutics, Inc.